J&J has launched two dose trials of its Code-19 vaccine candidate

J&J has launched two dose trials of its Code-19 vaccine candidate

LONDON: Johnson and Johnson on Monday launched a new large-scale late-stage experiment to test the two-dose method of an experimental Covid 19 vaccine and to evaluate the potential additional benefits of protection with a second dose. The trial began.
The U.S. drugmaker plans to enroll 30,000 participants in the study and run a food trial in parallel with 60,000 volunteers starting in September.
The UK intends to recruit 6,000 participants in the study, and the rest of the world will be involved in 19 cases involving the United States, Belgium, Colombia, France, Germany, the Philippines, South Africa and Spain. , It said.
Saul Fost, a professor of pediatric immunology and infectious diseases, said one of them would be given the first dose of a placebo or experimental shot, currently called Ad26COV2, followed by a second dose or placebo 57 days later. At University Hospital Southampton.
The trial follows positive interim findings from the company’s ongoing mid-term clinical study, which states that a single dose of its vaccine candidate produces a strong immune response and is generally tolerated. ۔
“The study will evaluate the efficacy of the vaccine after both the first and second doses to assess the potential additional benefits of protection against the virus and the duration of protection with the second dose,” J&J said in a statement.
Competing pharmaceutical maker Pfizer and Biotech said last week that their potential Covid-19 shot had demonstrated more than 90% effectiveness in interim data from a late-stage trial, raising hopes. That the epidemic vaccine may soon be ready for use.
Although Pfizer uses a new technology called RNA, a biotech vaccine messenger, J&J uses a cold virus in its body to respond to the genetic material from the coronavirus.
The platform, called Advocaat, is also used in the Ebola vaccine, which was approved earlier this year.
“It’s really important that we test different vaccines from many different manufacturers and then be able to ensure that they supply the UK and the global population.”
Recruitment to the study will be completed in March 2021 and the hearing will last for 12 months.

STAY TUNED WITH US FOR MORE INTERESTING CONTENT ONLY ON DESINEW.XYZ

Leave a Reply

Your email address will not be published. Required fields are marked *